Zealand Pharma A/S (ZEAL) Stock Analysis

What Zealand Pharma A/S does

Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S is a biotechnology firm focused on the discovery, development, and commercialization of peptide-based medications. The company's therapeutic pipeline and marketed products primarily address gastrointestinal and metabolic diseases, as well as other niche conditions with significant unmet medical needs. Currently, Zealand Pharma markets lixisenatide under the brand names Adlyxin and Lyxumia. Its product portfolio also includes Dasiglucagon, offered as a single-use syringe or autoinjector for managing severe hypoglycemia, congenital hyperinsulinism, and post-bariatric surgery hypoglycemia, alongside its use in a dual-hormone artificial pancreas for automated diabetes care. In its advanced development stage, Dasiglucagon is progressing through Phase III clinical trials for congenital hyperinsulinism. Another significant late-stage asset is glepaglutide, a long-acting GLP-2 analogue, also in Phase III trials for the treatment of short bowel syndrome. Zealand Pharma A/S has established key collaboration agreements with entities such as Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.

Key metrics

ETFs linked to ZEAL

Broad-market and Healthcare sector ETFs an investor holding Zealand Pharma A/S is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ZEAL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Zealand Pharma A/S?

Zealand Pharma A/S trades under the ticker ZEAL on NASDAQ.

Which exchange is ZEAL listed on?

ZEAL is listed on NASDAQ.

What sector does Zealand Pharma A/S operate in?

Zealand Pharma A/S is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ZEAL in a portfolio?

PortView shows ZEAL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.